Epidemiology and Outcome of Glioblastoma
Эпидемиология и исходы глиобластомы
2017-09-21
SCID: 54.1/a5f5c83z
Discuss with AI
Genomic analysisGlioblastomaMolecular epidemiologyPrimary brain tumorSurvival outcomes
Figures from the paper
Abstract (AI)
Glioblastoma (GBM) is the most aggressive malignant primary brain tumor. With an incidence rate of 3.19 per 100,000 persons in the United States and a median age of 64 years, it is uncommon in children. The incidence is 1.6 times higher in males compared to females and 2.0 times higher in Caucasians compared to Africans and Afro-Americans, with lower incidence in Asians and American Indians. GBM is commonly located in the supratentorial region (frontal, temporal, parietal, and occipital lobes) and is rarely located in cerebellum. Genetic and environmental factors have been investigated in GBM. Risk factors include prior radiotherapy, decreased susceptibility to allergy, immune factors and immune genes, as well as some single nucleotide polymorphisms detected by genomic analysis. Use of anti-inflammatory medication has been found to be protective against GBM. Survival from GBM is poor; only few patients survive 2.5 years and less than 5% of patients survive 5 years following diagnosis. Survival rates for patients with GBM have shown no notable improvement in population statistics in the last three decades. Molecular epidemiology integrates molecular technology into epidemiological studies and outcomes. The future of the epidemiology of GBM will depend on multicenter studies generating large clinical data sets of genomic data potentially leading to further understanding of the roles of genes and environment in the development of this devastating disease.
Key Findings
1
Future progress depends on multicenter molecular epidemiology studies combining large clinical and genomic datasets to clarify genetic and environmental contributions to GBM.
2
GBM incidence is 1.6 times higher in males than females and 2.0 times higher in Caucasians than Africans and Afro-Americans, with lower rates in Asians and American Indians.
3
GBM usually arises in the supratentorial brain, whereas cerebellar tumors are rare; it is also uncommon in children.
4
Glioblastoma has an incidence of 3.19 per 100,000 persons in the United States and a median diagnosis age of 64 years.
5
Prognosis remains poor: fewer than 5% of patients survive five years, and population-level survival has not notably improved over the past three decades.
6
Reported risk factors include prior radiotherapy, reduced allergy susceptibility, immune-related factors and genes, and selected single-nucleotide polymorphisms, while anti-inflammatory medication may be protective.
Research Object
Glioblastoma (GBM)
Research Subject
The epidemiology, risk factors, molecular and environmental determinants, and clinical outcomes of GBM, including incidence, survival, and prognosis
Publication Details
Publication Date
2017-09-21
Journal
Publisher
ISSN
Cited by
567
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest